Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome.
Ontology highlight
ABSTRACT: OBJECTIVE:Rituximab is an effective treatment for children with steroid dependent or frequently relapsing nephrotic syndrome. The optimum dosing schedule for rituximab has not been established. We hypothesized that a single low dose of 375 mg/m2 would have comparable outcomes to higher doses in reducing the frequency of relapse and time to B cell reconstitution. METHODS:We conducted a multicenter retrospective observational cohort study of children with steroid-sensitive frequently relapsing nephrotic syndrome. Data were extracted from clinical records including the dates of diagnosis, treatment, relapses, the use of concomitant immunosuppression, and lymphocyte subset profiling. Patients treated earlier received variable doses of rituximab, although typically two doses of 750 mg/m2. Later
SUBMITTER: Maxted AP
PROVIDER: S-EPMC6424916 | biostudies-literature | 2019 May
REPOSITORIES: biostudies-literature
ACCESS DATA